Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5962
    +0.0025 (+0.42%)
     

  • NZD/EUR

    0.5556
    +0.0010 (+0.18%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    83.11
    +0.30 (+0.36%)
     

  • GOLD

    2,341.10
    +2.70 (+0.12%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,076.77
    +36.39 (+0.45%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,003.01
    -85.69 (-0.47%)
     

  • Hang Seng

    17,269.04
    +67.77 (+0.39%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • NZD/JPY

    92.7560
    +0.6410 (+0.70%)
     

J&J Nears Sale of Sylvant to U.K. Drugmaker Eusa Pharma

Manuel Baigorri
J&J Nears Sale of Sylvant to U.K. Drugmaker Eusa Pharma

A unit of U.S. health-care giant Johnson & Johnson has agreed to sell global rights to a treatment for a rare blood disorder to Britain’s Eusa Pharma. Eusa Pharma is buying the rights to the drug Sylvant from Janssen Sciences Ireland UC for $115 million in cash, the Hemel Hempstead, England-based company said Wednesday, confirming a Bloomberg report. Eusa Pharma is working to focus its operations fully on treatments for oncology and rare diseases.

Continue reading